Cytokinetics Inc
cytokinetics.comCytokinetics (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on developing small molecule drug candidates that modulate muscle function. Revenue has come primarily from collaboration and licensing agreements rather than product sales, as the company's pipeline candidates had not yet reached commercial stage as of the 10-K filed February 26, 2026. Key partnership agreements named in the filing include arrangements with Astellas (Fast Skeletal Regulatory Activator Agreement, dated April 23, 2020) and a License Agreement with Bayer AG. The company's pipeline targets cardiovascular and musculoskeletal diseases, with clinical programs including aficamten for non-obstructive hypertrophic cardiomyopathy (ACACIA-HCM trial) and a Phase 2 program (AMBER-HFpEF) in heart failure with preserved ejection fraction. Cytokinetics carries convertible senior notes due 2026 (4.0%), 2027 (3.50%), and 2031 (1.75%), reflecting a debt-funded operating model typical of pre-commercial biotech. The company does not pay a dividend.
Products & Services
Aficamten, a cardiac myosin inhibitor in clinical trials for non-obstructive hypertrophic cardiomyopathy (ACACIA-HCM) and a Phase 2 program targeting heart failure with preserved ejection fraction (AMBER-HFpEF), as disclosed in the 10-K filed 2026-02-26.
Revenue Model
Collaboration and licensing revenue from partnership agreements, including with Astellas and Bayer AG, rather than commercial product sales as of the filing date (10-K, filed 2026-02-26).
Customers & Markets
Pharmaceutical partners including Astellas and Bayer AG. End markets are cardiovascular and musculoskeletal diseases, specifically hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
Financial Snapshot
Loading...
